OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders

June 18, 2021 4:42 PM EDT | Source: Klein Law Firm

New York, New York--(Newsfile Corp. - June 18, 2021) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that the Company violated federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/88062_952524_logo.jpg

Class Period: February 2, 2021 and June 10, 2021
Lead Plaintiff Deadline: August 17, 2021

Learn more about your recoverable losses in OCGN:
https://www.kleinstocklaw.com/pslra-1/ocugen-inc-loss-submission-form?id=17012&from=5

The filed complaint alleges that Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Shareholders have until August 17, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

For additional information about the OCGN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88062

info